header image

Posts from ‘September, 2011’

MicroDose Therapeutx Begins Phase 1 Trial Of MDT-637 For Treatment of Respiratory Syncytial Virus

MicroDose Therapeutx Begins Phase 1 Trial Of MDT-637 For Treatment of Respiratory Syncytial Virus

Monmouth Junction, NJ, September 27, 2011 — MicroDose Therapeutx, Inc. today announced that the first human subject has been dosed in a Phase 1 clinical trial of MDT-637, MicroDose’s inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV).  This Phase 1 trial follows the reactivation of the United States IND for MDT-637 as re-formulated for delivery using MicroDose’s proprietary dry powder nebulizer.

The Phase 1 clinical trial is a U.S.-based, single ascending dose, randomized, placebo controlled trial studying the safety, tolerability and pharmacokinetics of MDT-637 in 48 healthy adult subjects.